{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:51:48Z","timestamp":1790272308697,"version":"4.1.0"},"reference-count":170,"publisher":"American Society of Hematology","issue":"15","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,8,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Older adults with acute myeloid leukemia (AML) represent a vulnerable population in whom disease-based and clinical risk factors, patient goals, prognosis, and practitioner- and patient-perceived treatment risks and benefits influence treatment recommendations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>These evidence-based guidelines of the American Society of Hematology (ASH) are intended to support patients, clinicians, and other health care professionals in their decisions about management of AML in older adults.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>ASH formed a multidisciplinary guideline panel that included specialists in myeloid leukemia, geriatric oncology, patient-reported outcomes and decision-making, frailty, epidemiology, and methodology, as well as patients. The McMaster Grading of Recommendations Assessment, Development and Evaluation (GRADE) Centre supported the guideline-development process, including performing systematic evidence reviews (up to 24 May 2019). The panel prioritized clinical questions and outcomes according to their importance to patients, as judged by the panel. The panel used the GRADE approach, including GRADE\u2019s Evidence-to-Decision frameworks, to assess evidence and make recommendations, which were subject to public comment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The panel agreed on 6 critical questions in managing older adults with AML, mirroring real-time practitioner-patient conversations: the decision to pursue antileukemic treatment vs best supportive management, the intensity of therapy, the role and duration of postremission therapy, combination vs monotherapy for induction and beyond, duration of less-intensive therapy, and the role of transfusion support for patients no longer receiving antileukemic therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Treatment is recommended over best supportive management. More-intensive therapy is recommended over less-intensive therapy when deemed tolerable. However, these recommendations are guided by the principle that throughout a patient\u2019s disease course, optimal care involves ongoing discussions between clinicians and patients, continuously addressing goals of care and the relative risk-benefit balance of treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2020001920","type":"journal-article","created":{"date-parts":[[2020,8,6]],"date-time":"2020-08-06T15:49:37Z","timestamp":1596728977000},"page":"3528-3549","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":174,"title":["American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults"],"prefix":"10.1182","volume":"4","author":[{"given":"Mikkael A.","family":"Sekeres","sequence":"first","affiliation":[{"name":"Leukemia Program, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon","family":"Guyatt","sequence":"additional","affiliation":[{"name":"Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Abel","sequence":"additional","affiliation":[{"name":"Leukemia Division, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shabbir","family":"Alibhai","sequence":"additional","affiliation":[{"name":"Institute of Medical Sciences, Department of Medicine, University of Toronto, Toronto, ON, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica K.","family":"Altman","sequence":"additional","affiliation":[{"name":"Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rena","family":"Buckstein","sequence":"additional","affiliation":[{"name":"Odette Cancer Centre, Division of Medical Oncology and Hematology, Department of Medicine, Sunnybrook Health Sciences Centre, Toronto, ON, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Choe","sequence":"additional","affiliation":[{"name":"Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pinkal","family":"Desai","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1093-2189","authenticated-orcid":false,"given":"Harry","family":"Erba","sequence":"additional","affiliation":[{"name":"Department of Medicine, School of Medicine, Duke University, Durham, NC;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6189-8067","authenticated-orcid":false,"given":"Christopher S.","family":"Hourigan","sequence":"additional","affiliation":[{"name":"National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0546-7895","authenticated-orcid":false,"given":"Thomas W.","family":"LeBlanc","sequence":"additional","affiliation":[{"name":"Department of Medicine, School of Medicine, Duke University, Durham, NC;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9816-6302","authenticated-orcid":false,"given":"Mark","family":"Litzow","sequence":"additional","affiliation":[{"name":"Division of Hematology, Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"MacEachern","sequence":"additional","affiliation":[{"name":"Grand River Regional Cancer Centre, Kitchener, ON, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura C.","family":"Michaelis","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudipto","family":"Mukherjee","sequence":"additional","affiliation":[{"name":"Leukemia Program, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"O\u2019Dwyer","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, University of Rochester, Rochester, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Rosko","sequence":"additional","affiliation":[{"name":"Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Stone","sequence":"additional","affiliation":[{"name":"Leukemia Division, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0931-7851","authenticated-orcid":false,"given":"Arnav","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Toronto, Toronto, ON, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7737-4914","authenticated-orcid":false,"given":"L. E.","family":"Colunga-Lozano","sequence":"additional","affiliation":[{"name":"Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada;"},{"name":"Health Science Center, Department of Clinical Medicine, Universidad de Guadalajara, Guadalajara, Mexico; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaping","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5160-5144","authenticated-orcid":false,"given":"QiuKui","family":"Hao","sequence":"additional","affiliation":[{"name":"Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada;"},{"name":"The Center of Gerontology and Geriatrics\/National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romina","family":"Brignardello-Petersen","sequence":"additional","affiliation":[{"name":"Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2020,8,6]]},"reference":[{"issue":"3","key":"2020080611342194400_B1","doi-asserted-by":"crossref","first-page":"E123","DOI":"10.1503\/cmaj.131237","article-title":"Guidelines 2.0: systematic development of a comprehensive checklist for a successful guideline enterprise","volume":"186","author":"Sch\u00fcnemann","year":"2014","journal-title":"CMAJ"},{"key":"2020080611342194400_B2","volume-title":"Clinical Practice Guidelines We Can Trust","author":"Institute of Medicine (US) Committee on Standards for Developing Trustworthy Clinical Practice Guidelines","year":"2011"},{"issue":"7","key":"2020080611342194400_B3","doi-asserted-by":"crossref","first-page":"525","DOI":"10.7326\/0003-4819-156-7-201204030-00009","article-title":"Guidelines International Network: toward international standards for clinical practice guidelines","volume":"156","author":"Qaseem","year":"2012","journal-title":"Ann Intern Med"},{"issue":"7","key":"2020080611342194400_B4","doi-asserted-by":"crossref","first-page":"548","DOI":"10.7326\/M14-1885","article-title":"Guidelines International Network: principles for disclosure of interests and management of conflicts in guidelines","volume":"163","author":"Sch\u00fcnemann","year":"2015","journal-title":"Ann Intern Med"},{"key":"2020080611342194400_B5","doi-asserted-by":"crossref","first-page":"i2089","DOI":"10.1136\/bmj.i2089","article-title":"GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 2: Clinical practice guidelines","volume":"353","author":"Alonso-Coello","year":"2016","journal-title":"BMJ"},{"key":"2020080611342194400_B6","doi-asserted-by":"crossref","first-page":"i2016","DOI":"10.1136\/bmj.i2016","article-title":"GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 1: Introduction","volume":"353","author":"Alonso-Coello","year":"2016","journal-title":"BMJ"},{"issue":"1","key":"2020080611342194400_B7","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1472-6963-4-38","article-title":"Systems for grading the quality of evidence and the strength of recommendations I: critical appraisal of existing approaches The GRADE Working Group","volume":"4","author":"Atkins","year":"2004","journal-title":"BMC Health Serv Res"},{"issue":"4","key":"2020080611342194400_B8","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"issue":"7650","key":"2020080611342194400_B9","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"7","key":"2020080611342194400_B10","first-page":"677","article-title":"Letters, numbers, symbols and words: how to communicate grades of evidence and recommendations","volume":"169","author":"Sch\u00fcnemann","year":"2003","journal-title":"CMAJ"},{"key":"2020080611342194400_B11","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jclinepi.2016.01.032","article-title":"GRADE Guidelines: 16. GRADE evidence to decision frameworks for tests in clinical practice and public health","volume":"76","author":"Sch\u00fcnemann","year":"2016","journal-title":"J Clin Epidemiol"},{"key":"2020080611342194400_B12","unstructured":"Social Security Administration. Actuarial Life Table. 2016. https:\/\/www.ssa.gov\/oact\/STATS\/table4c6.html. Accessed 2 October 2019."},{"key":"2020080611342194400_B13","unstructured":"National Cancer Institute Surveillance, Epidemiology, and End Results Program. SEER*Explorer. 2019. https:\/\/seer.cancer.gov\/explorer\/. Accessed 2 October 2019."},{"key":"2020080611342194400_B14","unstructured":"National Cancer Institute Surveillance, Epidemiology, and End Results Program. Cancer Stat Facts: Leukemia\u2013Acute Myeloid Leukemia (AML). Vol 2019. https:\/\/seer.cancer.gov\/statfacts\/html\/amyl.html. Accessed 2 October 2019."},{"key":"2020080611342194400_B15","author":"Hogan"},{"key":"2020080611342194400_B16","article-title":"Projected Age Groups and Sex Composition of the Population: Main Projections Series for the United States, 2017-2060","author":"Census Bureau"},{"key":"2020080611342194400_B17","unstructured":"The World Bank. World Bank staff estimates based on age\/sex distributions of United Nations Population Division's World Population Prospects: 2019 revision. https:\/\/data.worldbank.org\/indicator\/SP.POP.65UP.TO.ZS. Accessed 2 October 2019."},{"key":"2020080611342194400_B18","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1182\/asheducation-2014.1.14","article-title":"Treating acute myeloid leukemia in older adults","volume":"2014","author":"Wang","year":"2014","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"6","key":"2020080611342194400_B19","first-page":"669","article-title":"Development of therapeutic agents for older patients with acute myelogenous leukemia","volume":"11","author":"Hourigan","year":"2010","journal-title":"Curr Opin Investig Drugs"},{"issue":"5","key":"2020080611342194400_B20","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1182\/blood-2014-08-551499","article-title":"How I treat the older patient with acute myeloid leukemia","volume":"125","author":"Ossenkoppele","year":"2015","journal-title":"Blood"},{"key":"2020080611342194400_B21","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1182\/asheducation-2016.1.339","article-title":"Fitness in the elderly: how to make decisions regarding acute myeloid leukemia induction","volume":"2016","author":"Rao","year":"2016","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"2020080611342194400_B22","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1200\/EDBK_239097","article-title":"More versus less therapy for older adults with acute myeloid leukemia: new perspectives on an old debate","volume":"39","author":"Klepin","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"11","key":"2020080611342194400_B23","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.3324\/haematol.2018.191536","article-title":"Genetics of acute myeloid leukemia in the elderly: mutation spectrum and clinical impact in intensively treated patients aged 75 years or older","volume":"103","author":"Prassek","year":"2018","journal-title":"Haematologica"},{"issue":"33","key":"2020080611342194400_B24","doi-asserted-by":"crossref","first-page":"5580","DOI":"10.1200\/JCO.2009.22.2547","article-title":"Age-specific differences in oncogenic pathway dysregulation and anthracycline sensitivity in patients with acute myeloid leukemia","volume":"27","author":"Rao","year":"2009","journal-title":"J Clin Oncol"},{"issue":"5","key":"2020080611342194400_B25","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1182\/blood.V98.5.1312","article-title":"The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial","volume":"98","author":"Grimwade","year":"2001","journal-title":"Blood"},{"issue":"9","key":"2020080611342194400_B26","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1182\/blood-2005-09-3724","article-title":"Age and acute myeloid leukemia","volume":"107","author":"Appelbaum","year":"2006","journal-title":"Blood"},{"issue":"1","key":"2020080611342194400_B27","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/sj.leu.2404004","article-title":"Attitude towards remission induction for elderly patients with acute myeloid leukemia influences survival","volume":"20","author":"Juliusson","year":"2006","journal-title":"Leukemia"},{"issue":"14","key":"2020080611342194400_B28","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1001\/archinte.162.14.1597","article-title":"The outcomes and costs of acute myeloid leukemia among the elderly","volume":"162","author":"Menzin","year":"2002","journal-title":"Arch Intern Med"},{"issue":"7","key":"2020080611342194400_B29","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s00277-015-2351-x","article-title":"Big data analysis of treatment patterns and outcomes among elderly acute myeloid leukemia patients in the United States","volume":"94","author":"Medeiros","year":"2015","journal-title":"Ann Hematol"},{"issue":"4","key":"2020080611342194400_B30","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.bbmt.2015.10.019","article-title":"Outcomes of allogeneic stem cell transplantation in elderly patients with acute myeloid leukemia: a systematic review and meta-analysis","volume":"22","author":"Rashidi","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"2020080611342194400_B31","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/sj.leu.2403289","article-title":"Decision-making and quality of life in older adults with acute myeloid leukemia or advanced myelodysplastic syndrome","volume":"18","author":"Sekeres","year":"2004","journal-title":"Leukemia"},{"issue":"4","key":"2020080611342194400_B32","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jclinepi.2010.09.012","article-title":"GRADE guidelines: 2. Framing the question and deciding on important outcomes","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"2020080611342194400_B33","article-title":"Assessing risk of bias in included studies","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2011"},{"key":"2020080611342194400_B34","unstructured":"National Cancer Institute Surveillance, Epidemiology, and End Results Program. SEER*Stat Database: Incidence - SEER 9 Regs Research Data, Nov 2015 Sub (1973-2013) &lt;Katrina\/Rita Population Adjustment&gt;. Linked To County Attributes - Total U.S., 1969-2014 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2016, based on the November 2015 submission. https:\/\/seer.cancer.gov\/data-software\/documentation\/seerstat\/nov2015\/. Accessed 27 November 2019."},{"issue":"1","key":"2020080611342194400_B35","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1182\/blood-2011-04-347872","article-title":"Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007","volume":"119","author":"Dores","year":"2012","journal-title":"Blood"},{"issue":"4","key":"2020080611342194400_B36","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1158\/1055-9965.EPI-12-1356","article-title":"Cancer survivors in the United States: prevalence across the survivorship trajectory and implications for care","volume":"22","author":"de Moor","year":"2013","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"18","key":"2020080611342194400_B37","doi-asserted-by":"crossref","first-page":"4179","DOI":"10.1182\/blood-2008-07-172007","article-title":"Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry","volume":"113","author":"Juliusson","year":"2009","journal-title":"Blood"},{"issue":"4","key":"2020080611342194400_B38","doi-asserted-by":"crossref","first-page":"594","DOI":"10.3324\/haematol.12304","article-title":"Improvements in survival of adults diagnosed with acute myeloblastic leukemia in the early 21st century","volume":"93","author":"Pulte","year":"2008","journal-title":"Haematologica"},{"issue":"1","key":"2020080611342194400_B39","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1200\/JCO.2007.15.4245","article-title":"Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group","volume":"27","author":"B\u00fcchner","year":"2009","journal-title":"J Clin Oncol"},{"issue":"12","key":"2020080611342194400_B40","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1056\/NEJMoa1112304","article-title":"Prognostic relevance of integrated genetic profiling in acute myeloid leukemia","volume":"366","author":"Patel","year":"2012","journal-title":"N Engl J Med"},{"issue":"9","key":"2020080611342194400_B41","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1182\/blood-2014-11-610543","article-title":"Acute myeloid leukemia ontogeny is defined by distinct somatic mutations","volume":"125","author":"Lindsley","year":"2015","journal-title":"Blood"},{"issue":"13","key":"2020080611342194400_B42","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1182\/blood-2010-02-270330","article-title":"Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: the Southwest Oncology Group (SWOG) experience","volume":"116","author":"Medeiros","year":"2010","journal-title":"Blood"},{"issue":"2","key":"2020080611342194400_B43","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1182\/blood.V60.2.309.309","article-title":"Causes of initial remission induction failure in acute myelogenous leukemia","volume":"60","author":"Estey","year":"1982","journal-title":"Blood"},{"issue":"11","key":"2020080611342194400_B44","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1200\/JCO.1989.7.11.1637","article-title":"Efficacy of intensive chemotherapy for acute myelogenous leukemia associated with a preleukemic syndrome","volume":"7","author":"Gajewski","year":"1989","journal-title":"J Clin Oncol"},{"issue":"4","key":"2020080611342194400_B45","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/BF01703440","article-title":"Acute myeloid leukemia in the elderly: biological features and search for adequate treatment","volume":"63","author":"Heinemann","year":"1991","journal-title":"Ann Hematol"},{"issue":"2","key":"2020080611342194400_B46","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1053\/j.seminhematol.2006.01.003","article-title":"Treatment of older patients with acute myeloid leukemia\u2013new agents","volume":"43","author":"Burnett","year":"2006","journal-title":"Semin Hematol"},{"issue":"1","key":"2020080611342194400_B47","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.beha.2007.11.006","article-title":"Older adults: should the paradigm shift from standard therapy?","volume":"21","author":"Estey","year":"2008","journal-title":"Best Pract Res Clin Haematol"},{"issue":"4","key":"2020080611342194400_B48","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1053\/j.seminoncol.2008.04.013","article-title":"Acute myeloid leukemia in the elderly","volume":"35","author":"Dombret","year":"2008","journal-title":"Semin Oncol"},{"issue":"3","key":"2020080611342194400_B49","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/leu.2014.234","article-title":"Comorbidity and performance status in acute myeloid leukemia patients: a nation-wide population-based cohort study","volume":"29","author":"\u00d8stg\u00e5rd","year":"2015","journal-title":"Leukemia"},{"issue":"12","key":"2020080611342194400_B50","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.3324\/haematol.2012.066100","article-title":"Survival for older patients with acute myeloid leukemia: a population-based study","volume":"97","author":"Oran","year":"2012","journal-title":"Haematologica"},{"issue":"3","key":"2020080611342194400_B51","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s40258-013-0032-2","article-title":"Medicare fee-for-service enrollees with primary acute myeloid leukemia: an analysis of treatment patterns, survival, and healthcare resource utilization and costs","volume":"11","author":"Meyers","year":"2013","journal-title":"Appl Health Econ Health Policy"},{"issue":"13","key":"2020080611342194400_B52","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1002\/cncr.24373","article-title":"Outcomes and quality of care in acute myeloid leukemia over 40 years","volume":"115","author":"Alibhai","year":"2009","journal-title":"Cancer"},{"issue":"4","key":"2020080611342194400_B53","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1111\/j.1365-2141.2006.06476.x","article-title":"The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia","volume":"136","author":"Giles","year":"2007","journal-title":"Br J Haematol"},{"issue":"12","key":"2020080611342194400_B54","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.3324\/haematol.13309","article-title":"Risk factors and decision criteria for intensive chemotherapy in older patients with acute myeloid leukemia","volume":"93","author":"Malfuson","year":"2008","journal-title":"Haematologica"},{"issue":"12","key":"2020080611342194400_B55","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1001\/jamaoncol.2017.2714","article-title":"Development and validation of a novel acute myeloid leukemia-composite model to estimate risks of mortality","volume":"3","author":"Sorror","year":"2017","journal-title":"JAMA Oncol"},{"issue":"21","key":"2020080611342194400_B56","doi-asserted-by":"crossref","first-page":"4287","DOI":"10.1182\/blood-2012-12-471680","article-title":"Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia","volume":"121","author":"Klepin","year":"2013","journal-title":"Blood"},{"issue":"5","key":"2020080611342194400_B57","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/jgs.15835","article-title":"Function, survival, and care utilization among older adults with hematologic malignancies","volume":"67","author":"DuMontier","year":"2019","journal-title":"J Am Geriatr Soc"},{"issue":"5","key":"2020080611342194400_B58","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1001\/jamaoncol.2017.5674","article-title":"Prevalence of cognitive impairment and association with survival among older patients with hematologic cancers","volume":"4","author":"Hshieh","year":"2018","journal-title":"JAMA Oncol"},{"issue":"4","key":"2020080611342194400_B59","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1182\/blood.2019000758","article-title":"Gait speed, grip strength, and clinical outcomes in older patients with hematologic malignancies","volume":"134","author":"Liu","year":"2019","journal-title":"Blood"},{"issue":"5","key":"2020080611342194400_B60","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1038\/leu.2011.9","article-title":"Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720","volume":"25","author":"Baer","year":"2011","journal-title":"Leukemia"},{"issue":"8","key":"2020080611342194400_B61","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1002\/cncr.22976","article-title":"Impact of remission induction chemotherapy on survival in older adults with acute myeloid leukemia","volume":"110","author":"Baz","year":"2007","journal-title":"Cancer"},{"issue":"12","key":"2020080611342194400_B62","doi-asserted-by":"crossref","first-page":"E244","DOI":"10.1002\/ajh.23848","article-title":"Intensive chemotherapy, azacitidine, or supportive care in older acute myeloid leukemia patients: an analysis from a regional healthcare network","volume":"89","author":"Bories","year":"2014","journal-title":"Am J Hematol"},{"issue":"3","key":"2020080611342194400_B63","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/j.1365-2141.2009.07604.x","article-title":"The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial","volume":"145","author":"Burnett","year":"2009","journal-title":"Br J Haematol"},{"issue":"3","key":"2020080611342194400_B64","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1182\/blood-2015-01-621664","article-title":"International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with &gt;30% blasts","volume":"126","author":"Dombret","year":"2015","journal-title":"Blood"},{"issue":"1","key":"2020080611342194400_B65","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1182\/blood-2005-11-4354","article-title":"Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461","volume":"108","author":"Cancer and Leukemia Group B 8461","year":"2006","journal-title":"Blood"},{"issue":"12","key":"2020080611342194400_B66","doi-asserted-by":"crossref","first-page":"5129","DOI":"10.1182\/blood-2007-02-069666","article-title":"Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial","volume":"109","author":"Gardin","year":"2007","journal-title":"Blood"},{"issue":"7","key":"2020080611342194400_B67","doi-asserted-by":"crossref","first-page":"e287","DOI":"10.1016\/j.clml.2018.05.005","article-title":"Predictive and prognostic markers in adults with acute myeloid leukemia: a single-institution experience","volume":"18","author":"Gbadamosi","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"3","key":"2020080611342194400_B68","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/ajh.23908","article-title":"Characterization and prognostic features of secondary acute myeloid leukemia in a population-based setting: a report from the Swedish Acute Leukemia Registry","volume":"90","author":"Huleg\u00e5rdh","year":"2015","journal-title":"Am J Hematol"},{"issue":"1","key":"2020080611342194400_B69","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/ajh.23337","article-title":"Fludarabine, cytarabine, and attenuated-dose idarubicin (m-FLAI) combination therapy for elderly acute myeloid leukemia patients","volume":"88","author":"Kim","year":"2013","journal-title":"Am J Hematol"},{"issue":"11","key":"2020080611342194400_B70","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1038\/sj.leu.2403528","article-title":"Phase III study of all-trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemia","volume":"18","author":"Schlenk","year":"2004","journal-title":"Leukemia"},{"issue":"26","key":"2020080611342194400_B71","doi-asserted-by":"crossref","first-page":"4027","DOI":"10.1182\/blood-2013-12-546283","article-title":"Valproic acid in combination with all-trans retinoic acid and intensive therapy for acute myeloid leukemia in older patients [published correction appears in Blood. 2015;125(19):3037]","volume":"123","author":"Tassara","year":"2014","journal-title":"Blood"},{"issue":"1","key":"2020080611342194400_B72","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1046\/j.1365-2141.2001.03043.x","article-title":"Prognostic significance of risk group stratification in elderly patients with acute myeloid leukaemia","volume":"115","author":"Wahlin","year":"2001","journal-title":"Br J Haematol"},{"issue":"11","key":"2020080611342194400_B73","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/j.leukres.2015.08.005","article-title":"Azacitidine in the treatment of older patients affected by acute myeloid leukemia: a report by the Rete Ematologica Pugliese (REP)","volume":"39","author":"Delia","year":"2015","journal-title":"Leuk Res"},{"issue":"3","key":"2020080611342194400_B74","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1200\/JCO.2011.40.3642","article-title":"Superior long-term outcome with idarubicin compared with high-dose daunorubicin in patients with acute myeloid leukemia age 50 years and older","volume":"31","author":"Gardin","year":"2013","journal-title":"J Clin Oncol"},{"issue":"10","key":"2020080611342194400_B75","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1002\/cncr.21006","article-title":"Disease biology rather than age is the most important determinant of survival of patients &gt; or = 60 years with acute myeloid leukemia treated with uniform intensive therapy","volume":"103","author":"Gupta","year":"2005","journal-title":"Cancer"},{"issue":"11","key":"2020080611342194400_B76","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1007\/s00277-017-3104-9","article-title":"Therapeutic decision-making in elderly patients with acute myeloid leukemia: conventional intensive chemotherapy versus hypomethylating agent therapy","volume":"96","author":"Oh","year":"2017","journal-title":"Ann Hematol"},{"issue":"10","key":"2020080611342194400_B77","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1200\/JCO.2014.58.0571","article-title":"Prognostic significance of NPM1 mutations in the absence of FLT3-internal tandem duplication in older patients with acute myeloid leukemia: a SWOG and UK National Cancer Research Institute\/Medical Research Council report","volume":"33","author":"Ostronoff","year":"2015","journal-title":"J Clin Oncol"},{"issue":"1","key":"2020080611342194400_B78","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1159\/000437131","article-title":"High-intensity induction chemotherapy is feasible for elderly patients with acute myeloid leukemia","volume":"135","author":"Shacham-Abulafia","year":"2016","journal-title":"Acta Haematol"},{"issue":"9","key":"2020080611342194400_B79","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.leukres.2013.05.013","article-title":"Geriatric assessment in older patients with acute myeloid leukemia: a retrospective study of associated treatment and outcomes","volume":"37","author":"Sherman","year":"2013","journal-title":"Leuk Res"},{"issue":"3","key":"2020080611342194400_B80","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.clml.2015.11.016","article-title":"Clofarabine plus low-dose cytarabine is as effective as and less toxic than intensive chemotherapy in elderly AML patients","volume":"16","author":"Takahashi","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"4","key":"2020080611342194400_B81","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1002\/ajh.23654","article-title":"Azacitidine in untreated acute myeloid leukemia: a report on 149 patients","volume":"89","author":"Th\u00e9pot","year":"2014","journal-title":"Am J Hematol"},{"issue":"8","key":"2020080611342194400_B82","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.leukres.2013.03.022","article-title":"Azacitidine results in comparable outcome in newly diagnosed AML patients with more or less than 30% bone marrow blasts","volume":"37","author":"van der Helm","year":"2013","journal-title":"Leuk Res"},{"issue":"2","key":"2020080611342194400_B83","first-page":"387","article-title":"Treatment selection of elderly acute myeloid leukemia patients guided by HCT-CI score [in Chinese]","volume":"25","author":"Zhang","year":"2017","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"issue":"2","key":"2020080611342194400_B84","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1179\/102453312X13221316477651","article-title":"Pretreatment risk factors and importance of comorbidity for overall survival, complete remission, and early death in patients with acute myeloid leukemia","volume":"17","author":"Djunic","year":"2012","journal-title":"Hematology"},{"issue":"5-6","key":"2020080611342194400_B85","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.tracli.2015.06.249","article-title":"Economic analysis of blood product transfusions according to the treatment of acute myeloid leukemia in the elderly","volume":"22","author":"Cannas","year":"2015","journal-title":"Transfus Clin Biol"},{"issue":"2","key":"2020080611342194400_B86","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1080\/10245332.2001.11746560","article-title":"Survival from acute myeloid leukaemia in patients over 55 years of age in Northern Ireland: a discrete population","volume":"6","author":"McMullin","year":"2001","journal-title":"Hematology"},{"issue":"6","key":"2020080611342194400_B87","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1590\/S0100-879X2003000600004","article-title":"Acute myeloid leukemia in elderly patients: experience of a single center","volume":"36","author":"Rodrigues","year":"2003","journal-title":"Braz J Med Biol Res"},{"issue":"7","key":"2020080611342194400_B88","doi-asserted-by":"crossref","first-page":"26","DOI":"10.17116\/terarkh201587726-32","article-title":"Clinical and epidemiological characteristics of acute myeloid leukemias in adults according to the data of municipal hematology departments in Moscow [in Russian]","volume":"87","author":"Semochkin","year":"2015","journal-title":"Ter Arkh"},{"issue":"2","key":"2020080611342194400_B89","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1007\/s12254-012-0011-6","article-title":"Treatment outcome in AML: a single-centre experience in an unselected patient cohort","volume":"5","author":"Strasser-Weippl","year":"2012","journal-title":"Memo"},{"key":"2020080611342194400_B90","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1756-8722-6-29","article-title":"Azacitidine might be beneficial in a subgroup of older AML patients compared to intensive chemotherapy: a single centre retrospective study of 227 consecutive patients","volume":"6","author":"van der Helm","year":"2013","journal-title":"J Hematol Oncol"},{"issue":"4","key":"2020080611342194400_B91","first-page":"957","article-title":"Analysis of efficacy and prognosis of induction chemotherapy in 76 elderly patients with acute myeloid leukemia (non-APL) [in Chinese]","volume":"22","author":"Yang","year":"2014","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"issue":"2","key":"2020080611342194400_B92","doi-asserted-by":"crossref","first-page":"95","DOI":"10.5045\/br.2014.49.2.95","article-title":"Clinical characteristics and treatment outcome of acute myeloid leukemia in elderly patients in Korea: a retrospective analysis","volume":"49","author":"Yi","year":"2014","journal-title":"Blood Res"},{"issue":"2","key":"2020080611342194400_B93","first-page":"79","article-title":"Efficacy of remission induction chemotherapy and prognostic analysis in elderly patients with acute myeloid leukemia [in Chinese]","volume":"33","author":"Zheng","year":"2012","journal-title":"Chung Hua Hsueh Yeh Hsueh Tsa Chi"},{"issue":"9","key":"2020080611342194400_B94","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1200\/JCO.2015.64.0060","article-title":"Gemtuzumab ozogamicin versus best supportive care in older patients with newly diagnosed acute myeloid leukemia unsuitable for intensive chemotherapy: Results of the randomized phase III EORTC-GIMEMA AML-19 Trial","volume":"34","author":"Amadori","year":"2016","journal-title":"J Clin Oncol"},{"issue":"12","key":"2020080611342194400_B95","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1007\/s00277-015-2489-6","article-title":"Decitabine versus best supportive care in older patients with refractory anemia with excess blasts in transformation (RAEBt) - results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group (GMDSSG)","volume":"94","author":"Becker","year":"2015","journal-title":"Ann Hematol"},{"issue":"4","key":"2020080611342194400_B96","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s00277-019-03600-6","article-title":"Treatment patterns and comparative analysis of non-intensive regimens in elderly acute myeloid leukemia patients-a real-world experience from India","volume":"98","author":"Kanakasetty","year":"2019","journal-title":"Ann Hematol"},{"issue":"15","key":"2020080611342194400_B97","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1200\/JCO.2010.30.9245","article-title":"Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group","volume":"29","author":"L\u00fcbbert","year":"2011","journal-title":"J Clin Oncol"},{"issue":"8","key":"2020080611342194400_B98","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1054\/bjoc.1999.1123","article-title":"Treatment, long-term outcome and prognostic variables in 214 unselected AML patients in Sweden","volume":"82","author":"Astr\u00f6m","year":"2000","journal-title":"Br J Cancer"},{"issue":"5","key":"2020080611342194400_B99","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/hon.2900100503","article-title":"The management of acute myelogenous leukemia in the elderly: ten-year experience in 118 patients","volume":"10","author":"Bassan","year":"1992","journal-title":"Hematol Oncol"},{"issue":"8","key":"2020080611342194400_B100","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1080\/1042819031000082993","article-title":"Acute myeloid leukemia in elderly patients aged over 75 years: experience of a single centre [letter]","volume":"44","author":"Di Febo","year":"2003","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"2020080611342194400_B101","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1200\/JCO.2009.23.8329","article-title":"Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia","volume":"28","author":"Fenaux","year":"2010","journal-title":"J Clin Oncol"},{"issue":"6","key":"2020080611342194400_B102","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1182\/blood-2009-01-198093","article-title":"A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older","volume":"114","author":"Harousseau","year":"2009","journal-title":"Blood"},{"issue":"1","key":"2020080611342194400_B103","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1080\/10428194.2016.1180688","article-title":"Treatment patterns and comparative effectiveness in elderly acute myeloid leukemia patients (age 70 years or older): the Lyon-university hospital experience","volume":"58","author":"Heiblig","year":"2017","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2020080611342194400_B104","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s00432-015-2045-8","article-title":"Long-term follow-up of the AML97 study for patients aged 60 years and above with acute myeloid leukaemia: a study of the East German Haematology and Oncology Study Group (OSHO)","volume":"142","author":"Kahl","year":"2016","journal-title":"J Cancer Res Clin Oncol"},{"issue":"3","key":"2020080611342194400_B105","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1159\/000362777","article-title":"Selection of elderly acute myeloid leukemia patients for intensive chemotherapy: effectiveness of intensive chemotherapy and subgroup analysis","volume":"133","author":"Kim","year":"2015","journal-title":"Acta Haematol"},{"issue":"2","key":"2020080611342194400_B106","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s12185-014-1617-8","article-title":"Role of induction and consolidation chemotherapy in elderly acute myeloid leukemia patients","volume":"100","author":"Kim","year":"2014","journal-title":"Int J Hematol"},{"issue":"1","key":"2020080611342194400_B107","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/ajco.12331","article-title":"Treatment of elderly patients with acute myeloid leukemia with azacitidine results in fewer hospitalization days and infective complications but similar survival compared with intensive chemotherapy","volume":"11","author":"Lao","year":"2015","journal-title":"Asia Pac J Clin Oncol"},{"issue":"2","key":"2020080611342194400_B108","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1093\/annonc\/mdj112","article-title":"Acute myelogenous leukemia in elderly patients not eligible for intensive chemotherapy: the dark side of the moon","volume":"17","author":"Latagliata","year":"2006","journal-title":"Ann Oncol"},{"issue":"2","key":"2020080611342194400_B109","first-page":"167","article-title":"Acute nonlymphocytic leukemia in the elderly: results of a retrospective study","volume":"74","author":"Latagliata","year":"1989","journal-title":"Haematologica"},{"issue":"2","key":"2020080611342194400_B110","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s40261-016-0469-9","article-title":"Comparison of reduced-intensity idarubicin and daunorubicin plus cytarabine as induction chemotherapy for elderly patients with newly diagnosed acute myeloid leukemia","volume":"37","author":"Liu","year":"2017","journal-title":"Clin Drug Investig"},{"issue":"11","key":"2020080611342194400_B111","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.clml.2016.08.006","article-title":"An evaluation of treatment patterns and outcomes in elderly patients newly diagnosed with acute myeloid leukemia: a retrospective analysis of electronic medical records from US community oncology practices","volume":"16","author":"Ma","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"43","key":"2020080611342194400_B112","first-page":"6380","article-title":"Treatment of acute myeloid leukemia in the elderly with low-dose cytosine arabinoside [in Danish]","volume":"156","author":"Pedersen","year":"1994","journal-title":"Ugeskr Laeger"},{"issue":"5","key":"2020080611342194400_B113","first-page":"533","article-title":"Therapeutic outcomes of older patients with acute myeloid leukemia","volume":"31","author":"Sajid","year":"2010","journal-title":"Saudi Med J"},{"issue":"7","key":"2020080611342194400_B114","doi-asserted-by":"crossref","first-page":"e6207","DOI":"10.5867\/medwave.2015.07.6207","article-title":"Response and survival in acute myeloid leukemia patients not candidates to transplantation treated with azacitidine versus palliative treatment: a retrospective study","volume":"15","author":"Sarmiento Maldonado","year":"2015","journal-title":"Medwave"},{"issue":"2","key":"2020080611342194400_B115","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/1097-0142(19880115)61:2<227::AID-CNCR2820610204>3.0.CO;2-J","article-title":"Treatment of acute myeloid leukemia in elderly patients. A retrospective study","volume":"61","author":"Sebban","year":"1988","journal-title":"Cancer"},{"issue":"1","key":"2020080611342194400_B116","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s12955-018-0897-8","article-title":"Social preferences for health states associated with acute myeloid leukemia for patients undergoing treatment in the United Kingdom","volume":"16","author":"Castej\u00f3n","year":"2018","journal-title":"Health Qual Life Outcomes"},{"key":"2020080611342194400_B117"},{"issue":"8","key":"2020080611342194400_B118","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1080\/14656566.2018.1465562","article-title":"Advancements in the management of medically less-fit and older adults with newly diagnosed acute myeloid leukemia","volume":"19","author":"Michaelis","year":"2018","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"2020080611342194400_B119","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s40273-018-0704-8","article-title":"Health state utilities for acute myeloid leukaemia: a time trade-off study","volume":"37","author":"Joshi","year":"2019","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"2020080611342194400_B120","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1186\/s12955-018-1013-9","article-title":"Assessing utility values for treatment-related health states of acute myeloid leukemia in the United States","volume":"16","author":"Stein","year":"2018","journal-title":"Health Qual Life Outcomes"},{"issue":"4","key":"2020080611342194400_B121","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3390\/ijms18040837","article-title":"Clinical outcomes of 217 patients with acute erythroleukemia according to treatment type and line: a retrospective multinational study","volume":"18","author":"Almeida","year":"2017","journal-title":"Int J Mol Sci"},{"issue":"16","key":"2020080611342194400_B122","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1002\/cncr.30704","article-title":"Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach","volume":"123","author":"Boddu","year":"2017","journal-title":"Cancer"},{"issue":"30","key":"2020080611342194400_B123","doi-asserted-by":"crossref","first-page":"e4182","DOI":"10.1097\/MD.0000000000004182","article-title":"The outcome and prognostic factors of 248 elderly patients with acute myeloid leukemia treated with standard-dose or low-intensity induction therapy","volume":"95","author":"Chen","year":"2016","journal-title":"Medicine (Baltimore)"},{"issue":"45","key":"2020080611342194400_B124","doi-asserted-by":"crossref","first-page":"79126","DOI":"10.18632\/oncotarget.15988","article-title":"Azacitidine or intensive chemotherapy for older patients with secondary or therapy-related acute myeloid leukemia","volume":"8","author":"Dumas","year":"2017","journal-title":"Oncotarget"},{"issue":"16","key":"2020080611342194400_B125","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.1002\/cncr.29430","article-title":"Health care utilization and end-of-life care for older patients with acute myeloid leukemia","volume":"121","author":"El-Jawahri","year":"2015","journal-title":"Cancer"},{"issue":"12","key":"2020080611342194400_B126","doi-asserted-by":"crossref","first-page":"4343","DOI":"10.1182\/blood.V99.12.4343","article-title":"Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside","volume":"99","author":"Estey","year":"2002","journal-title":"Blood"},{"issue":"8","key":"2020080611342194400_B127","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.clml.2015.02.022","article-title":"Effect of age on treatment decision-making in elderly patients with acute myeloid leukemia","volume":"15","author":"Fattoum","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"4","key":"2020080611342194400_B128","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1002\/cncr.26354","article-title":"Azacitidine for the treatment of patients with acute myeloid leukemia: report of 82 patients enrolled in an Italian Compassionate Program","volume":"118","author":"Maurillo","year":"2012","journal-title":"Cancer"},{"issue":"4","key":"2020080611342194400_B129","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s00277-017-3217-1","article-title":"Outcomes of previously untreated elderly patients with AML: a propensity score-matched comparison of clofarabine vs. FLAG","volume":"97","author":"Scappaticci","year":"2018","journal-title":"Ann Hematol"},{"issue":"1","key":"2020080611342194400_B130","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1186\/s12885-017-3803-6","article-title":"Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens","volume":"17","author":"Seymour","year":"2017","journal-title":"BMC Cancer"},{"issue":"10","key":"2020080611342194400_B131","first-page":"5631","article-title":"The response to induction therapy is crucial for the treatment outcomes of elderly patients with acute myeloid leukemia: single-institution experience","volume":"34","author":"Tasaki","year":"2014","journal-title":"Anticancer Res"},{"key":"2020080611342194400_B132","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.leukres.2018.10.011","article-title":"Intensive chemotherapy vs. hypomethylating agents in older adults with newly diagnosed high-risk acute myeloid leukemia: A single center experience","volume":"75","author":"Vachhani","year":"2018","journal-title":"Leuk Res"},{"issue":"21","key":"2020080611342194400_B133","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1056\/NEJMoa1605949","article-title":"TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes","volume":"375","author":"Welch","year":"2016","journal-title":"N Engl J Med"},{"issue":"3","key":"2020080611342194400_B134","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/s41375-019-0704-5","article-title":"Recent drug approvals for newly diagnosed acute myeloid leukemia: gifts or a Trojan horse?","volume":"34","author":"Estey","year":"2020","journal-title":"Leukemia"},{"key":"2020080611342194400_B135","first-page":"658","article-title":"Systematic reviews of economic burden and healthrelated quality of life (HRQoL) in patients with acute myeloid leukaemia (AML) [abstract]","volume":"2","author":"Bosshard","year":"2018","journal-title":"HemaSphere"},{"issue":"21","key":"2020080611342194400_B136","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.2699.2699","article-title":"Decitabine is more cost effective than standard conventional induction therapy in elderly acute myeloid leukemia patients [abstract]","volume":"122","author":"Batty","year":"2013","journal-title":"Blood"},{"issue":"32","key":"2020080611342194400_B137","doi-asserted-by":"crossref","first-page":"3678","DOI":"10.1200\/JCO.2017.73.6728","article-title":"Effects of education and income on treatment and outcome in patients with acute myeloid leukemia in a tax-supported health care system: a national population-based cohort study","volume":"35","author":"\u00d8stg\u00e5rd","year":"2017","journal-title":"J Clin Oncol"},{"issue":"24","key":"2020080611342194400_B138","doi-asserted-by":"crossref","first-page":"4496","DOI":"10.1200\/JCO.2003.02.133","article-title":"6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group","volume":"21","author":"B\u00fcchner","year":"2003","journal-title":"J Clin Oncol"},{"issue":"28","key":"2020080611342194400_B139","doi-asserted-by":"crossref","first-page":"4747","DOI":"10.1200\/JCO.2008.21.0674","article-title":"Acute myeloid leukemia with translocation (8;21) or inversion (16) in elderly patients treated with conventional chemotherapy: a collaborative study of the French CBF-AML intergroup","volume":"27","author":"Pr\u00e9bet","year":"2009","journal-title":"J Clin Oncol"},{"issue":"9","key":"2020080611342194400_B140","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.bbmt.2014.05.019","article-title":"Mobilization-driven postconsolidation therapy in elderly patients with acute myeloid leukemia: feasibility and efficacy of autologous stem cell transplantation versus low-dose gemtuzumab ozogamicin","volume":"20","author":"Capelli","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"2020080611342194400_B141","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.3324\/haematol.11068","article-title":"Adding lomustine to idarubicin and cytarabine for induction chemotherapy in older patients with acute myeloid leukemia: the BGMT 95 trial results","volume":"92","author":"Pigneux","year":"2007","journal-title":"Haematologica"},{"issue":"4","key":"2020080611342194400_B142","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/sj.leu.2404122","article-title":"Intensive consolidation versus oral maintenance therapy in patients 61 years or older with acute myeloid leukemia in first remission: results of second randomization of the AML HD98-B treatment Trial","volume":"20","author":"Schlenk","year":"2006","journal-title":"Leukemia"},{"issue":"4","key":"2020080611342194400_B143","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1007\/s12185-017-2389-8","article-title":"Prospective randomization of post-remission therapy comparing autologous peripheral blood stem cell transplantation versus high-dose cytarabine consolidation for acute myelogenous leukemia in first remission","volume":"107","author":"Miyamoto","year":"2018","journal-title":"Int J Hematol"},{"issue":"13","key":"2020080611342194400_B144","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1182\/blood-2009-10-246470","article-title":"Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study","volume":"115","author":"L\u00f6wenberg","year":"2010","journal-title":"Blood"},{"key":"2020080611342194400_B145","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.leukres.2016.12.001","article-title":"Consolidation with autologous stem cell transplantation in first remission is safe and effective in AML patients above 65 years","volume":"53","author":"Heini","year":"2017","journal-title":"Leuk Res"},{"issue":"10","key":"2020080611342194400_B146","doi-asserted-by":"crossref","first-page":"e427","DOI":"10.1016\/S2352-3026(15)00148-9","article-title":"Post-remission treatment with allogeneic stem cell transplantation in patients aged 60 years and older with acute myeloid leukaemia: a time-dependent analysis","volume":"2","author":"Versluis","year":"2015","journal-title":"Lancet Haematol"},{"issue":"suppl 2","key":"2020080611342194400_B147","article-title":"The QUAZAR AML-001 Maintenance Trial: Results of a phase III international, randomized, double-blind, placebo-controlled study of CC-486 (oral formulation of azacitidine) in patients with acute myeloid leukemia (AML) in first remission","volume":"134","author":"Wei","year":"2019","journal-title":"Blood"},{"issue":"7","key":"2020080611342194400_B148","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/leu.2011.59","article-title":"The addition of arsenic trioxide to low-dose Ara-C in older patients with AML does not improve outcome","volume":"25","author":"Burnett","year":"2011","journal-title":"Leukemia"},{"issue":"1","key":"2020080611342194400_B149","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/leu.2012.229","article-title":"The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison","volume":"27","author":"Burnett","year":"2013","journal-title":"Leukemia"},{"issue":"2","key":"2020080611342194400_B150","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41375-018-0312-9","article-title":"Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome","volume":"33","author":"Cortes","year":"2019","journal-title":"Leukemia"},{"issue":"21","key":"2020080611342194400_B151","doi-asserted-by":"crossref","first-page":"6430","DOI":"10.1158\/1078-0432.CCR-17-1423","article-title":"Outcome of azacitidine therapy in acute myeloid leukemia is not improved by concurrent vorinostat therapy but is predicted by a diagnostic molecular signature","volume":"23","author":"Craddock","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"19","key":"2020080611342194400_B152","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1182\/blood-2014-10-608117","article-title":"Vosaroxin and vosaroxin plus low-dose Ara-C (LDAC) vs low-dose Ara-C alone in older patients with acute myeloid leukemia","volume":"125","author":"Dennis","year":"2015","journal-title":"Blood"},{"issue":"2","key":"2020080611342194400_B153","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S1470-2045(18)30010-X","article-title":"Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study","volume":"19","author":"DiNardo","year":"2018","journal-title":"Lancet Oncol"},{"issue":"9","key":"2020080611342194400_B154","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1182\/blood-2014-03-560557","article-title":"Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy","volume":"124","author":"D\u00f6hner","year":"2014","journal-title":"Blood"},{"key":"2020080611342194400_B155","doi-asserted-by":"crossref","first-page":"167029","DOI":"10.1155\/2015\/167029","article-title":"Decitabine compared with low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia: a pilot study of safety, efficacy, and cost-effectiveness","volume":"2015","author":"Jacob","year":"2015","journal-title":"Adv Hematol"},{"issue":"21","key":"2020080611342194400_B156","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1200\/JCO.2011.38.9429","article-title":"Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia","volume":"30","author":"Kantarjian","year":"2012","journal-title":"J Clin Oncol"},{"issue":"2","key":"2020080611342194400_B157","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/leu.2016.303","article-title":"A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials [published correction appears in Leukemia. 2017;31(7):1659]","volume":"31","author":"Montalban-Bravo","year":"2017","journal-title":"Leukemia"},{"issue":"12","key":"2020080611342194400_B158","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1200\/JCO.2013.50.3102","article-title":"Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905","volume":"32","author":"Prebet","year":"2014","journal-title":"J Clin Oncol"},{"issue":"24","key":"2020080611342194400_B159","doi-asserted-by":"crossref","first-page":"4840","DOI":"10.1182\/blood-2012-06-436055","article-title":"Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia","volume":"120","author":"Quint\u00e1s-Cardama","year":"2012","journal-title":"Blood"},{"issue":"24","key":"2020080611342194400_B160","doi-asserted-by":"crossref","first-page":"3608","DOI":"10.1182\/bloodadvances.2018023689","article-title":"Randomized trial of 10 days of decitabine \u00b1 bortezomib in untreated older patients with AML: CALGB 11002 (Alliance)","volume":"2","author":"Roboz","year":"2018","journal-title":"Blood Adv"},{"issue":"1","key":"2020080611342194400_B161","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3324\/haematol.2012.066613","article-title":"Randomized phase IIb study of low-dose cytarabine and lintuzumab versus low-dose cytarabine and placebo in older adults with untreated acute myeloid leukemia","volume":"98","author":"Sekeres","year":"2013","journal-title":"Haematologica"},{"issue":"1","key":"2020080611342194400_B162","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/2162-3619-3-10","article-title":"Survival and hospitalization among patients with acute myeloid leukemia treated with azacitidine or decitabine in a large managed care population: a real-world, retrospective, claims-based, comparative analysis. [published correction appears in Exp Hematol Oncol. 2014;3:19]","volume":"3","author":"Smith","year":"2014","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"2020080611342194400_B163","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/trf.14413","article-title":"Red blood cell transfusion in adult palliative care: a systematic review","volume":"58","author":"Chin-Yee","year":"2018","journal-title":"Transfusion"},{"issue":"1","key":"2020080611342194400_B164","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1089\/jpm.2013.0387","article-title":"Transfusion in palliative cancer patients: a review of the literature","volume":"17","author":"Uceda Torres","year":"2014","journal-title":"J Palliat Med"},{"issue":"17","key":"2020080611342194400_B165","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1002\/cncr.30735","article-title":"Why are patients with blood cancers more likely to die without hospice?","volume":"123","author":"Odejide","year":"2017","journal-title":"Cancer"},{"issue":"7","key":"2020080611342194400_B166","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1182\/blood-2018-03-842575","article-title":"Transfusion dependence, use of hospice services, and quality of end-of-life care in leukemia","volume":"132","author":"LeBlanc","year":"2018","journal-title":"Blood"},{"issue":"8","key":"2020080611342194400_B167","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1002\/cncr.29913","article-title":"Intensity of end-of-life care for patients with myelodysplastic syndromes: Findings from a large national database","volume":"122","author":"Fletcher","year":"2016","journal-title":"Cancer"},{"key":"2020080611342194400_B168","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jclinepi.2016.09.009","article-title":"GRADE Evidence to Decision (EtD) frameworks for adoption, adaptation, and de novo development of trustworthy recommendations: GRADE-ADOLOPMENT","volume":"81","author":"Sch\u00fcnemann","year":"2017","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"2020080611342194400_B169","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1016\/S2352-3026(18)30182-0","article-title":"Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial","volume":"6","author":"Short","year":"2019","journal-title":"Lancet Haematol"},{"issue":"16","key":"2020080611342194400_B170","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1182\/bloodadvances.2018015529","article-title":"Evaluation of induction chemotherapies after hypomethylating agent failure in myelodysplastic syndromes and acute myeloid leukemia","volume":"2","author":"Ball","year":"2018","journal-title":"Blood Adv"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/15\/3528\/1751528\/advancesadv2020001920c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/15\/3528\/1751528\/advancesadv2020001920c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,6]],"date-time":"2020-08-06T15:52:35Z","timestamp":1596729155000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/4\/15\/3528\/461693\/American-Society-of-Hematology-2020-guidelines-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,6]]},"references-count":170,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2020,8,11]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2020001920","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,6]]}}}